Shares of semiconductor design software leader Synopsys experienced their most severe single-day decline in company history following a disastrous quarterly earnings report. The stock collapsed by more than 35 percent, erasing billions in market value and triggering multiple fraud investigations. This historic market rout stems from a perfect storm of financial underperformance and geopolitical pressures.
Financial Performance Misses Dramatically
The crisis unfolded with the release of Synopsys’ third-quarter 2025 fiscal results. The company reported revenue of $1.74 billion, falling substantially short of the $1.77 billion analysts had projected. Even more concerning was the adjusted earnings per share of $3.39, which missed the consensus estimate of $3.74 by a wide margin.
Particularly alarming was the severe contraction in the Design-IP segment, which accounts for nearly one-quarter of total revenue. This business unit saw revenues plummet by 7.7 percent to $427.6 million, representing a dramatic reversal from years of consistent growth.
Geopolitical and Customer Challenges
CEO Sassine Ghazi identified two primary factors behind the disappointing results. U.S. export restrictions disrupted design projects in China, while significant issues emerged with a major foundry client. Industry experts suspect Intel is the customer in question, following the chip giant’s scaling back of its 18A foundry technology initiatives.
The ongoing trade tensions between the United States and China proved particularly damaging to Synopsys. For over a month beginning in late May, export controls prevented the company from selling its chip design software to Chinese customers—a market that represents more than ten percent of industry revenues.
Should investors sell immediately? Or is it worth buying Synopsys?
Although these restrictions were lifted in July, the damage to customer confidence appears lasting. Market researchers at Piper Sandler noted that “confidence among Chinese clients has been shaken, with their willingness to spend having diminished considerably.”
Guidance Shock and Workforce Reductions
The final blow to investor confidence came from a drastic reduction in full-year guidance. Synopsys slashed its earnings expectations to a range of $12.76 to $12.80 per share, representing a 16 percent decrease from the previous forecast of $15.11 to $15.19.
Compounding these challenges, the company announced plans to reduce its workforce by ten percent before the conclusion of fiscal year 2026. These cost-cutting measures follow the recent completion of the $35 billion Ansys acquisition in July—a major integration project that now must proceed under significantly worsened conditions.
Legal Fallout and Analyst Reactions
The historic share price decline wiped out approximately $15 billion in market capitalization and attracted immediate scrutiny from legal firms. Companies including Hagens Berman and Pomerantz are examining whether Synopsys may have misled investors regarding customer risks and growth prospects.
Wall Street responded with divided opinions. While Needham maintained its buy recommendation despite lowering its price target to $550, Rosenblatt downgraded the stock to “Neutral.” The path to recovery appears uncertain, with no clear timeline for when stability might return to the company’s operations.
Ad
Synopsys Stock: Buy or Sell?! New Synopsys Analysis from October 1 delivers the answer:
The latest Synopsys figures speak for themselves: Urgent action needed for Synopsys investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 1.
Synopsys: Buy or sell? Read more here...